New ‘Zapitor’ drug brings hope to Genotype A carriers

Following a recent comprehensive research programme, Active Genetics Ltd® are pleased to announce their latest groundbreaking findings. Trials have show that Genotype A carriers benefit from a new preventative medication, ‘Zapitor’.

The link between Genotype A and increased risk of heart disease has long been established within the scientific community. Active Genetics Ltd® have produced a new medication, that has been shown to dramatically reduce the incidence of heart disease in later life.

Dr Simon Forsyth said “taking just one ‘Zapitor’ pill a day, from an early age can prevent heart disease in Genotype A carriers. We feel this new medication will give peace of mind to thousands of Genotype A carriers worldwide.”